Jorge Juncos, MD
Neurology · Cumming, GANPI 1184801383
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 64.2% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $7,144 and has fallen 89.3% since, to $766 in 2025.
Across 143 payments — averaging $78.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$7K
- Acadia Pharmaceuticals Inc$945
- EMD Serono, Inc.$854
- AbbVie$466
- Neurocrine Biosciences, Inc.$409
- Biohaven Pharmaceutical Holding Company Ltd.$193
- plus $1K from 15 others
Across 48 payments — averaging $2384.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biohaven Pharmaceuticals, Inc.$72K
- Biohaven Pharmaceutical Holding Company Ltd.$30K
- MDD US Operations, LLC$13K
What the payments were for
- Consulting fees$5,12646%
- Travel & lodging$1,49213%
- Food & beverage$4,59641%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 11 | $7,216 |
| Acadia Pharmaceuticals Inc | 20 | $945 |
| EMD Serono, Inc. | 57 | $854 |
| AbbVie | 13 | $466 |
| Neurocrine Biosciences, Inc. | 9 | $409 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $193 |
| Supernus Pharmaceuticals, Inc. | 2 | $167 |
| Kyowa Kirin, Inc. | 4 | $148 |
| MDD US Operations, LLC | 5 | $138 |
| W. L. Gore & Associates, Inc. | 4 | $135 |
| Abbott | 1 | $128 |
| Amneal Pharmaceuticals LLC | 2 | $124 |
| Livanova USA, Inc. | 1 | $112 |
| Biogen | 4 | $72 |
| Lundbeck LLC | 1 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Harmony Biosciences LLC | 1 | $18 |
| Argenx US, Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AUSTEDO$7,041
- NUPLAZID$375
- INGREZZA$220
- NURTEC ODT$148
- INFINITY$128
- QELBREE$122
- VNS Therapy Symmetry Model 8103 Generator$112
- CREXONT$102
How this compares
$11,238 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ajovy AutoinjectorFremanezumab-Vfrm | 16 | $34,320 |
| OzempicSemaglutide | 11 | $9,082 |
| RytaryCarbidopa/Levodopa | 11 | $4,010 |
| Buprenorphine | 16 | $3,326 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 78 | $2,954 |
| AmantadineAmantadine Hcl | 23 | $873 |
| Pregabalin | 22 | $851 |
| Duloxetine Hcl | 26 | $607 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 16 | $320 |
| Escitalopram Oxalate | 33 | $308 |
| Clonazepam | 44 | $182 |
| Gabapentin | 17 | $170 |
| Tramadol Hcl | 13 | $161 |
| Lorazepam | 18 | $112 |
| Trazodone Hcl | 11 | $98 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary | $124 | $4,01011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.
Other neurology in Cumming
- Scott CooperCumming$283K
- Peter FutrellCumming$34K
- Frank PuhalovichCumming$33K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- John MorganAugusta$715K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.